The main data were given in a preview last week. So I don't think we will see much new in the study on thursday. However, we MIGHT see a little investor enthusiasm. There has already been national attention on Sarepta in a NYTimes article last week, so I doubt there will be more coverage in the science press. That said, taking a position now is probably not a bad idea. As we get closer to an FDA filing SRPT is likely to have upward pressure.